{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-138910","form_type":"8-K","ticker":null,"cik":"0001923840","company_name":"Third Harmonic Bio, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.225044+00:00","generated_at":"2026-06-01T23:41:58.969247+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"THRD reports Q1 net loss $7.9M; FDA clears THB335 IND; Phase 1 trial initiated","bullets":["Cash $262.8M as of Mar 31, 2024; expected to fund operations through at least 2026.","Net loss $7.9M for Q1 2024 vs $9.1M in Q1 2023; R&D expense $6.2M, G&A $5.1M.","FDA cleared IND for THB335 (oral KIT inhibitor); Phase 1 SAD/MAD trial initiated, results expected 1H 2025.","Leadership: Christopher Dinsmore CSO, Dennis Dean Chief Non-Clinical Dev Officer, Jennifer Dittman promoted to Chief Dev Ops Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-138910","json":"https://secwatch.observer/filing/0001193125-24-138910.json","markdown":"https://secwatch.observer/filing/0001193125-24-138910.md","text":"https://secwatch.observer/filing/0001193125-24-138910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1923840/000119312524138910/0001193125-24-138910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1923840/000119312524138910/d840135d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:41:58.969247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e305baad5377f50b0a5475dc5efc5e43dc9a6c4","claim":"Third Harmonic Bio, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"issued a press release reporting the Company’s financial results for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1923840/000119312524138910/0001193125-24-138910-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}